Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
IPO Year:
Exchange: NASDAQ
Website: pharming.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $14.00 | Buy | Jefferies |
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation. Presentations:Title: Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment With PI3Kδ I
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation. The Phase II clinical trial is a single arm, open-label, dose range-finding, multi-center
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023Fourth quarter operating profit increased to US$6.7 million from US$1.1 mil
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of March: 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET. For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at [email protected] or your Roth repres
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration:Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of February: Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website. For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please cont
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.
SC 13G/A - Pharming Group N.V. (0001828316) (Subject)
SC 13G - Pharming Group N.V. (0001828316) (Subject)
SC 13G - Pharming Group N.V. (0001828316) (Subject)
Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023Fourth quarter operating profit increased to US$6.7 million from US$1.1 mil
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration:Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register
Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced a recommended public cash offer to the shareholders of Abliva AB ("A
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Third quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarter 2023Overall
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration:Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BId118ac68d9
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Overall cash and marketable securities declined to US$161.8 million at the end of the second quarter 2024 from US$203.5 million a
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BI9232
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Overall cash and marketable securities of US$203.5 million at the end of the quarterPharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. ("Pharming" or "the C
Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 millionStrong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 millionOverall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end of 2022 Progressed leniolisib development for APDS in additional geographies and for pediatric patients, and leniolisib indication expansion to primary immunodeficiencies (PIDs) with immune dysregulation li
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
SCHEDULE 13G/A - Pharming Group N.V. (0001828316) (Subject)
6-K - Pharming Group N.V. (0001828316) (Filer)
20-F - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.
Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Dr. Richard Peters as Non-Executive director for a period of four years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of the Board of Directors with immediate effect. Deborah Jorn, Vice-Chair of the Board of Directors, commented: "On behalf of the Board, I would like to thank our outgoing Chairman, Paul Sekhri, for his leadership, over the past eight years. During his tenure as Chairman, Paul a
PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso